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Propensity score calibration (PSC) can be used to adjust for unmeasured confounders using a cross-sectional
validation study that lacks information on the disease outcome (Y ), under a strong surrogacy assumption. Using
directed acyclic graphs and path analysis, the authors developed a formula to predict the presence and magnitude
of the bias of PSC in the simplest setting of a binary exposure (T ) and 1 confounder (X ) that are observed in the
main study and 1 confounder (C) that is observed in the validation study only. PSC bias is predicted on the basis
of parameters that can be estimated from the data and a single unidentifiable parameter, the relative risk (RR)
associated with C (RRCY). The authors simulated 1,000 cohort studies each with a Poisson-distributed outcome Y,
varying parameter values over a wide range. When using the true parameter for RRCY, the formula predicts PSC
bias almost perfectly in this simple setting (correlation with observed bias over 24 scenarios assessed: r ¼ 0.998).
The authors conclude that the bias from PSC observed in certain scenarios can be estimated from the imbalance in
C between treated and untreated persons, after adjustment for X, in the validation study and assuming a range of
plausible values for the unidentifiable RRCY.
bias (epidemiology); confounding factors (epidemiology); epidemiologic methods; path analysis; propensity score;
propensity score calibration; research design
Abbreviations: CI, confidence interval; DAG, directed acyclic graph; EP, error-prone; GS, gold standard; IR, incidence rate;
IRR, incidence rate ratio; NSAID, nonsteroidal antiinflammatory drug; OR, odds ratio; PSC, propensity score calibration.
Uncontrolled confounding can be a major source of bias in
nonexperimental research. Investigators often lack measures
of important potential confounders, such as smoking and
body mass index in pharmacoepidemiologic studies that
use claims data and laboratory values or blood pressure
measurements in questionnaire-based studies. If individual
data on confounders not measured in all study participants
are available for a subsample or a validation study, these data
can be used to adjust for joint confounding by the variables
that are unobserved in the main study under reasonable as-
sumptions about the selection of participants into the vali-
dation study (1). If the validation study contains information
on the disease outcome of interest, the adjustment can be
achieved using methods for missing data, such as multiple
imputation, to adjust for the covariates that are missing in
the main study (2, 3). If the validation study does not contain
information on the disease outcome of interest, which is
often the case, unmodified imputation techniques fail, because
they assume availability of complete cases for imputation
and/or estimation (4). For this specific setting, we have pro-
posed propensity score calibration (PSC) (5, 6). PSC combines
propensity scores to adjust for confounding in the main study
(7) with methods for measurement error correction, specif-
ically regression calibration (8, 9), to adjust for the error in
the propensity score due to unmeasured covariates estimated
in the cross-sectional validation study.
So far, we have established that the validity of PSC is
dependent on a key assumption of regression calibration,
called surrogacy (10). For PSC, this assumption means that
the error-prone propensity score estimated in the main study
is independent of the disease outcome given the gold stan-
dard propensity score estimated in the validation study. This
assumption cannot be assessed in the cross-sectional valida-
tion study. So far, we have shown that surrogacy is violated
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when the direction of the confounding by the variable(s) ob-
served only in the validation study differs from the direction
of confounding of the variable(s) observed in the main study.
We have argued that the assumption of ‘‘unidirectionality’’ of
confounding, also assumed in other methods used to adjust
for uncontrolled confounding, might hold more often than
not (6).
Using directed acyclic graphs (DAGs), Greenland has
pointed out that surrogacy may not be as natural or credible
for the propensity score as it is for measurement error (see
the Acknowledgments). Here we present a framework for
PSC using DAGs and develop a formula for predicting the
presence and magnitude of the bias of PSC based on path
analysis using regression coefficients (11). We evaluated the
performance of this bias formula in simulations that address
scenarios in which we have shown PSC to be unbiased and
scenarios in which we have shown PSC to be biased, as well as
additional scenarios not assessed so far. We also implemented
it in an empirical example.
MATERIALS AND METHODS
DAGs and structural equations
A DAG consists of a set of points and a set of arcs joining
the points, each arc being marked with an arrow to show its
direction (12–14). A path is an ordered set of points on the
graph such that 1) there is an arc between each point and the
next (which may be forwards or backwards) and 2) no point
appears in the path more than once.
DAGs can be used to display causality assumptions. For
example, consider the DAG in Figure 1 (the labels on the
arcs will be explained below). This graph tells us that the
variables T and X both affect Y, that variable X affects T, that
T has no effect on X, and that Y has no effect on T or X.
Traditionally, error terms (random variables with mean 0 that
are uncorrelated with all other variables and error terms in
the DAG) are not shown but are assumed to exist at each






T ¼ fTðXÞ þ eT
but makes no assumptions about the form of the functions
fY and fT. If we assume that these functions are both linear,
the DAG represents the structural equation model
X¼ eX
T¼ k3X þ eT
Y¼ k1X þ k2T þ eY :
The parameters in the above model are causal: That is, if we
change X by DX while holding T fixed, we would expect to
see Y change by k1DX.
Given a set of data that we assume to be generated by
a given structural equation model, Wright (11) gave a method
of labeling each arc with a value, such that the observed
correlation between any 2 variables is given by the sum of the
values of all paths between the variables, where the value of
a path is the product of the values of each arc in the path. The
value of an arc X / Y is given by the correlation coefficient
for the correlation between X and Y, after conditioning on
a set of variables sufficient to block all other paths between
X and Y.
In general, a path is blocked (12–14) if either 1) the path
contains a collider (a node on the path at which 2 arrows
meet), and we do not condition on the collider or any of its
descendants, or 2) the path contains a chain i / z / j or
a fork i ) z / j, and we condition on the variable z. Thus, in
Figure 1, the path X / Y ) T is blocked by the variable Y,
a collider, and Wright would assign the value qXT to the path
X / T. To calculate the value of the arc T / Y, however,
we would need to block the path T ) X / Y by conditioning
on X. The value of this arc would then be qTYjX, where
this notation stands for the correlation between T and Y
conditional on X.
If we consider the DAG as representing a structural equation
model, it is preferable to work with regression coefficients
rather than correlation coefficients: What change in Y
would we expect to see if X changes by DX? A similar ap-
proach can be used to calculate the regression coefficients for
all predictors in a regression equation: The coefficient for
a given predictor is the sum of the values of all paths between
the predictor and the outcome which are not blocked by other
predictors in the regression model, and the value of a path is
the product of all of the arcs in that path. The regression co-
efficient for the regression of X on Y is not the same as that for
the regression of Y on X, however. The value of a path going
against the arrow is different from the value of a path going
with the arrow. We can use the parameters of the structural
equation model and Wright’s method only if we are mov-
ing in the direction of the arrows. For example, we can
obtain the observed conditional expectation of Y given X as
E½Y jX ¼ k1X þ k2E½T jX þ E½eY 
¼ k1X þ k2ðk3X þ E½eT jXÞ
¼ ðk1 þ k2k3ÞX:
This will not work for general paths, however. For exam-
ple, consider the expectation of Y given T. There are 2 paths










Figure 1. Directed acyclic graph for the effect of a treatment T on an
outcome Y, with the variable X acting as a confounder.
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the value of the arc T ) X, whereas what we know is the
value of the arc X / T. However, the value of a path point-
ing in the reverse direction can be calculated from the value
of a path pointing in the forward direction and the variances
of the variables that lie along the path. The details are given
in Web Appendix 1, which is posted on the Journal’s website
(http://aje.oxfordjournals.org/). If the value of the forward path
is k, then we will write the value of the reverse path as r(k).
Therefore, we can calculate the regression coefficient for
the regression of Y on T as k2 þ r(k3)k1. The causal effect of
T on Y is k2, and the difference in Y due to confounding by X
is r(k3)k1, with r(k3) being the difference in X required to
cause a difference of 1 in T and with k1 being the effect of
a unit difference in X on Y. If we include X in the regression
equation, this blocks the path T ) X / Y, so the regression
coefficient for T would then be k2, the true causal effect.
Regression calibration
Now suppose that we are unable to measure the confounder
X perfectly, and our measurement is Z ¼ f(X) þ ez, where ez
is a random disturbance from some distribution. Further, sup-
pose that Z is a linear function of X, that is, Z¼ k4Xþ ez. This
situation is shown in Figure 2. The corresponding structural
equation model is
X ¼ eX
Z ¼ k4X þ eZ
T ¼ k3X þ eT
Y ¼ k1X þ k2T þ eY :
We are now unable to control for X, since it is not ob-
served. We can adjust for Z, but this does not block the path
T ) X / Y. Nonetheless, adjusting for Z may improve our
estimate of the treatment effect, depending on the parameters
of the structural equation model. In the extremes, if k4 ¼ 0,
adjusting for Z will not affect the estimate, which will be
k2þ r(k3)k1, while if ez¼ 0, adjusting for Z will remove the
confounding completely.
If we write kZXY for the value of the arc X / Y when
controlling for a set of variables Z and if we write kXY for
the true causal effect of the arc, then kZXY ¼ kXY if and only
if Z blocks all paths between X and Y except the direct path
X / Y. Then the estimated treatment effect after adjusting
for Z is k2 þ rðkZ3 Þk1, and the regression equation for Y in






















The bias in the coefficient for T is rðkZ3 Þk1, which we cannot
estimate without measuring X. If we perform a validation study
in which we measure X, Z, and T, we can obtain estimates of
rðkZ3 Þ and k1 by fitting the regression of X on Z and T. The














The coefficient of T gives an estimate of rðkZ3 Þ, and dividing
the coefficient of Z in equation 1 by the coefficient of Z in
equation 2 gives k1. We can therefore calculate rðkZ3 Þk1, and
subtracting this from the coefficient of T in equation 1 gives
the true treatment effect, k2.
Regression calibration can also be used with a general-
ized linear model for Y, provided that the linear predictor
of Y follows a normal distribution. For example, if Y were
a count and Poisson regression were used to model it, the


























which is still a linear function of Z and T. To obtain the
expected count, equation 3 can be exponentiated:
E½Y jZ; T  ¼ expfE½logðYÞ jZ; Tg:
In what follows, Y will generally be a Poisson outcome
variable, and we will use a generalized linear model to
model it. For clarity, we will use k for all paths modeled with
linear regression and b for all paths modeled with another
generalized linear model.
Propensity score calibration
At first sight, an error-prone propensity score model looks









Figure 2. Directed acyclic graph for the effect of a treatment T on an












Figure 3. Directed acyclic graph illustrating the use of propensity
score calibration to estimate the effect of treatment T on outcome Y,
assuming surrogacy. (EP, error-prone; GS, gold standard).
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which are used to define the error-prone (EP) propensity score
and a further group C measured in the validation sample used to
define the gold standard (GS) propensity score. If we assume
that X and C are uncorrelated and that neither affects Y directly,
only through PGS, we get Figure 3.
Then when we fit a Poisson regression model for Y in
terms of PEP and T, we again have 2 paths from T to Y: directly





































Thus, we can again find rðkPEP2 Þ and rðk
T
4 Þk1 from a linear
regression of PGS on PEP and T, and then subtract rðkPEP2 Þ=
ðrðkT4 Þk
T
1 Þ times the coefficient of PEP from the coefficient
of T to obtain an unbiased estimate of b2. Bootstrapping can
be used to obtain a confidence interval for b2.
Surrogacy
Although Figure 3 looks very similar to Figure 2, it is less
plausible as a causal model. This says that neither X nor C
affects Y directly; they only affect it through the propensity
score. For example, if we were concerned about age as a po-
tential confounder, with mortality as the outcome, Figure 3
claims that age can only affect mortality through its influence
on treatment, not directly. Note that the absence of these
direct effects is not a condition for confounding control using
propensity scores. A more plausible causal model that allows
for direct effects of X and C on Y is shown in Figure 4.
Note the dotted arrow in Figure 4, labeled k5. This is
required because PGS is a collider, and if we adjust for
PGS (or one of its descendants, such as T), we will induce
a correlation between X and C, although X and C are not
correlated marginally. Therefore, the value of k5 is 0, but
kT5 is nonzero.
If we assume this model, then PGS does not act directly
on Y, but X and C do. Suppose that
E½Y jX;C; T  ¼ expfaXCT þ b4X þ b2T þ b3Cg: ð6Þ
We cannot estimate these parameters, since we do not have
information about Y and C on the same subjects. If we fit
















































In fact, rðkPEP;T1 Þ ¼ 0, since r2XjPEP ¼ 0, so the coefficient
for T in the Poisson regression equation for Y is
b2 þ rðkPEP2 Þrðk3Þb3g

. The formula that we used previ-
ously to obtain an unbiased estimate of the effect of treat-
ment (the coefficient of T in the Poisson regression of Y on




1 times the coefficient of























b4 þ kT5 b3
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, and the method of calculat-
ing the effect of treatment will be unbiased if either
rðkPEP2 Þ ¼ 0 (i.e., the treatment assignment is independent




score-calibrated estimate of the treatment effect may be
closer to the true value (if the signs of rðkPEP3 Þb3 and
b4þkT5 b3
kT1





To test the PSC bias predicted by the above formula
against the empirical PSC bias, we conducted a simulation
study with 2 independent continuous confounders X and C.
We will discuss generalizations below. We describe the sim-
ulation study in Web Appendix 2 and present the simulation
parameters and their values in Table 1.
Empirical example
To illustrate the implementation of PSC and of the pro-
posed PSC bias estimation, we use the setting where PSC
was first implemented (5), addressing the paradoxical inverse
association between the use of nonsteroidal antiinflammatory
drugs (NSAIDs) and short-term all-cause mortality in older














Figure 4. Directed acyclic graph illustrating the use of propensity
score calibration to estimate the effect of treatment T on outcome Y,
without assuming surrogacy. (EP, error-prone; GS, gold standard).
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RESULTS
Simulation study
We varied the incidence rate (IR) of disease IRY , the in-
cidence rate ratio (IRR) for the exposure-disease association
IRRTY, the odds ratio (OR) for the unobserved confounder-
exposure association ORCT , the IRR for the unobserved
confounder-disease association IRRCY , the size of the main
study Nmain, and the proportion of persons in the random
validation sample Pval around the value of the basic scenario,
while keeping all other parameters constant at the value of
the basic scenario (see italic type in Table 2). The true IRRTY
is 1.0 in all scenarios, except for the 2 rows with IRRTY ¼ 2
and IRRTY ¼ 0.5. We present the median crude IRRTY and
the median IRRTY adjusting for the observed covariate X
only.
For PSC, we present the median observed bias and the
median predicted bias according to equation 9 using study-
specific estimates for all parameters, with the exception of b3
(log IRRCY), where we substituted the true parameter. We also
present the median value and interquartile range for IRRTY ,
the median percentage of bias reduction, the percentage of
studies in which the 95% confidence interval covers the true
IRRTY , and a measure of surrogacy (S), with values close to
100 indicating that surrogacy holds.
In the basic scenario, the crude IRRTY is 0.42. Compared
with the IRRTY of 0.62 after control for confounding by the
observed covariate X, adjusting for the unmeasured con-
founder C using PSC leads to an almost unbiased median
IRRTY of 1.09 and therefore a bias reduction of 100%. The
95% confidence interval has nominal coverage, and a value
of 88% for our assessment of surrogacy (percentage of var-
iance in Y explained by PGS and PEP which is due to PGS)
indicates that surrogacy might be a reasonable assumption.
When we vary one parameter at a time, PSC is clearly
biased in some scenarios. The bias can be predicted almost
perfectly by the bias formula derived above as equation 9,
using the path analysis framework. The correlation between
the median predicted bias and the median observed bias over
the scenarios assessed is 0.998.
We recently characterized scenarios in which PSC is un-
biased on the basis of surrogacy. The results presented provide
a more refined view. Although obviously the inverse corre-
lation between bias and our measure of surrogacy is strong
(0.89 for the median values over the scenarios assessed),
the magnitude of bias is not well predicted by our measure
of surrogacy, and some scenarios show larger bias despite
less pronounced violation of surrogacy than others.
Empirical example
The crude hazard ratio for NSAID use and all-cause mor-
tality is 0.68 (95% confidence interval (CI): 0.66, 0.71).
Adjusting for age removes some of the confounding (hazard
ratio¼ 0.72, 95% CI: 0.70, 0.75). Using PSC to additionally
control for not having had an influenza shot (as a proxy for
frailty) results in a hazard ratio of 0.76 (95% CI: 0.73, 0.80).
The results of the PSC bias prediction are summarized in
Table 3. Assuming, for example, a mortality hazard ratio
of 2.0 for not having had a flu shot, the predicted bias for
the log hazard ratio was 0.040 (Table 3), resulting in a bias-
adjusted PSC estimate of the hazard ratio equal to 0.73.
DISCUSSION
Here we have presented a novel framework for PSC that
allows us to predict the presence and magnitude of bias and
thus correct for it when applying PSC in the simplest possible
Table 1. Parameters and Values Used in the Basic and Alternative Scenarios
Parameter Parameter Value(s)
Notation Meaning Basic Scenario Alternative Scenarios
PT Prevalence of exposure of interest (T) 0.20
IRY Incidence rate of disease (Y) 0.01 0.005, 0.05, 0.10
IRRTY Incidence rate ratio for association between
exposure (T) and disease (Y)
1.0 0.5, 2.0
ORXT Odds ratio for association between a measured
confounder (X) and exposure (T)
(independent of C)
0.5
IRRXY Incidence rate ratio for association between
a measured confounder (X) and disease (Y)
(independent of T and C)
2.0
ORCT Odds ratio for association between an
unmeasured confounder (C) and exposure (T)
(independent of X)
0.5 0.40, 0.67, 1.0, 1.5, 2.0, 2.5
IRRCY Incidence rate ratio for association between
an unmeasured confounder (C) and
disease (Y) (independent of T and X)
2.0 0.5, 0.67, 1.0, 1.5
Nmain Size of main study 10,000
Pval Proportion of observations in validation study 0.1 0.02, 0.05, 0.2, 0.5
Abbreviations: IR, incidence rate; IRR, incidence rate ratio; OR, odds ratio.
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Table 2. Crude and Adjusted Incidence Rate Ratios for the Exposure-Outcome (T-Y) Association (Crude, Adjusted for X Only, and Adjusted for X
and C Using Propensity Score Calibration)a
Parameterb and Value













0.005 0.42 0.62 0.05 0.00 75 1.00 95 79
0.01 0.42 0.62 0.06 0.09 100 1.09 95 88
0.05 0.42 0.63 0.07 0.06 113 1.07 90 98
0.10 0.43 0.64 0.07 0.06 114 1.07 86 99
IRRTY
2.0 0.85 1.27 0.06 0.09 118 2.18 93 95
1.0 0.42 0.62 0.06 0.09 100 1.09 95 88
0.5 0.21 0.31 0.06 0.07 79 0.54 93 95
ORCT
0.4 0.37 0.55 0.30 0.29 140 1.33 91 91
0.5 0.42 0.62 0.06 0.09 100 1.09 95 88
0.67 0.49 0.76 0.09 0.08 42 0.92 94 93
1.0 0.63 0.99 0.00 0.00 —h 1.00 96 54
1.5 0.82 1.29 0.47 0.51 57 1.67 75 10
2.0 0.99 1.55 1.07 1.10 135 3.00 25 6
2.5 1.13 1.74 1.67 1.54 189 4.69 6 6
IRRCY
0.5 0.99 1.54 1.09 1.04 132 2.83 27 6
0.67 0.82 1.27 0.87 0.83 156 2.29 55 14
1.0 0.64 0.98 0.57 0.54 — 1.71 81 50
1.5 0.49 0.76 0.27 0.29 100 1.33 90 85
2.0 0.42 0.62 0.06 0.09 100 1.09 95 88
IRRCY (ORCT ¼ 2.0)
0.5 0.41 0.62 0.06 0.00 100 1.00 95 93
0.67 0.50 0.75 0.27 0.26 119 1.30 93 83
1.0 0.64 0.98 0.56 0.56 — 1.75 83 48
1.5 0.84 1.31 0.86 0.86 139 2.38 53 12
2.0 0.99 1.55 1.07 1.10 135 3.00 25 6
Pval
0.02 0.42 0.63 0.08 0.10 100 1.11 91 81
0.05 0.42 0.63 0.06 0.09 100 1.09 94 91
0.1 0.42 0.62 0.06 0.09 100 1.09 95 88
0.2 0.42 0.63 0.06 0.10 100 1.10 94 97
0.5 0.42 0.63 0.06 0.09 100 1.09 94 98
Abbreviations: EP, error-prone; GS, gold standard; IR, incidence rate; IRR, incidence rate ratio; OR, odds ratio.
a Median values from 1,000 simulations for each scenario (row); true IRRTY ¼ 1 in all scenarios except when IRRTY is the parameter varied.
b For the definition and range of these parameters, refer to Table 1. Only 1 parameter is varied at a time, whereas all other parameters are kept
constant at the level of the basic scenario (italic typeface) presented in Table 1 (with the exception of the second series of rows for IRRCY, where
ORCT is 2.0 instead of 0.5 to show the importance of the direction of confounding by the unmeasured confounder C).
c Controlling for measured covariate X only.
d Using equation 9 and the true parameters for b3 (log IRRCY); all other parameters are estimated from the actual data.
e Median percentage of bias reduction according to Cochran (29): 0% equals no improvement over the analysis controlling for measured
covariate X only, and 100% equals no residual bias (truth).
f Coverage probability of the empirical 95% confidence interval (2.5th–97.5th percentiles) obtained from 1,000 bootstrap samples.
g Assessment of the surrogacy assumption for propensity score calibration: percentage of variance in Y explained by PSGS and PSEP which is
due to PSGS; calculated as the ratio of the likelihood ratio comparing the logistic regression model logit(Y) ¼ m#0 þ m#1T þ m#2PSGS with the nested
logistic regression model logit(Y) ¼ m$0 þ m$1T to the likelihood ratio comparing the logistic regression model logit(Y) ¼ m0 þ m1T þ m2PSGS þ m3PSEP
with the nested logistic regression model logit(Y) ¼ m$0 þ m$1T times 100. Values close to the maximum possible value (100%) indicate surrogacy.
h Undefined, since the expected value of the denominator is 0 (no bias controlling for observed covariate X only).
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setting with a single observed confounder and a single un-
observed confounder. The bias estimation is based on pa-
rameters that can be estimated in the main study and the
(external) cross-sectional validation study and a single un-
observable parameter IRRCY—that is, the association of the
unmeasured confounder with the outcome, which is estimable
only in a validation study with adequate numbers of disease
outcomes. This bias equation advances the applicability of
PSC as a sensitivity analysis in the setting of a cross-sec-
tional validation study, as shown in our empirical example.
Alternative sensitivity methods include performing maxi-
mum likelihood or multiple imputation with any parameters
needed for identification (e.g., IRRCY) set to various values, or
Bayesian analyses with various priors on these parameters.
Any method that tries to address uncontrolled confounding
without observing the joint distribution of the confounder
with exposure and disease will need to rely on strong as-
sumptions or prior distributions. Following the assumptions
for regression calibration, we evaluated surrogacy as a good
candidate and were able to show that a measure of surrogacy
indeed helped to separate scenarios in which PSC was biased
from scenarios in which PSC was unbiased in our simulation
studies. The scenarios where PSC was unbiased had in com-
mon the fact that the direction of confounding of the observed
confounder(s) X was the same as the direction of confounding
by the unobserved confounder C (5, 6). Here we present a more
refined view of bias encountered when applying PSC based
on a balance of the magnitudes of observed and unob-
served confounding rather than just the directions.
In our empirical example in Web Appendix 3, we assume
that NSAID use has no protective effect on mortality and
that any inverse association is thus attributable to confounding
(16). Jackson et al. (17) observed an implausible mortality
reduction of over 60% (relative risk ¼ 0.39) associated with
receipt of a flu shot prior to the flu season in older adults.
The most plausible explanation for both findings is unmea-
sured confounding by frailty: Patients close to death are less
likely to receive certain treatments, especially preventive
treatments (15). Thus, we used not having had a flu shot as
a proxy for frailty in our example. Not having had a flu shot
was associated with an approximately 50% lower prevalence
of NSAID use in the validation study, and our best guess is
that it is associated with increased mortality. Based on this
assumption and information on flu shots available only in
the validation data, PSC improves our estimate of the NSAID-
mortality association.
The major strength of the proposed bias formula is that, at
least under the assumption of independence of observed
and unobserved confounders, only 1 parameter needs to be
substituted. All others can be estimated from the data. Prior
knowledge on the relative risk associated with the unmeasured
confounder (IRRCY) might be easier to obtain than prior
knowledge on the association of the unobserved confounder
with exposure (ORCT). This can be seen in our empirical ex-
ample. Results from several nonexperimental studies indicate
that older adults not receiving the flu shot have approximately
twice the short-term mortality as those who receive a flu shot
(e.g., see Jackson et al. (17)). Data on the association between
NSAID use and having had a flu shot, however, are sparse
or nonexistent. Note that most of the flu shot-mortality as-
sociation can be observed prior to the flu season and thus is
probably due to unmeasured confounding by frailty; that
is, it is not causal (17, 18). We thus use the reported flu
shot-mortality hazard ratio that is confounded by frailty as
our best guess to estimate the PSC bias.
Unless a factor unobserved in the main study is supposed
to be a risk factor for disease, information on such a factor
will rarely be sought using a validation study. An intuitive
advantage of PSC is that it uses all of the information avail-
able in the cross-sectional validation study to estimate the
joint association between the observed and unobserved co-
variates and exposure (PGS). By sampling from prior distri-
butions for the relative risk associated with the unmeasured
confounder, PSC can be employed to create uncertainty in-
tervals for the target effect and thus become part of bias
analysis (19–22).
The major limitation of the proposed bias formula is that
it is based on the simplest setting of 2 covariates, one measured
(X) and one unmeasured (C). Because linear combinations
of multivariate-normal variables are normal, our results should









E(PGS) ¼ b0 þ bTT þ bPepPEP Validation bT r ðkPEP2 Þ 0.00395
E(C) ¼ b0 þ bPgsPGS þ bPepPEP Validation bPgs r ðkPEP3 Þ 21.88586
Log(k(tjT,X)/k0(t )) ¼ b0 þ bTT þ bCC Not applicableb bC b3 0.693b
E(C) ¼ b0 þ bTT þ bXX Validation bX kT5 0.00268
Log(k(tjT,X)/k0(t )) ¼ b0 þ bTT þ bXX Main bX b4 0.04564
E(PGS) ¼ b0 þ bTT þ bXX Validation bX kT1 0.00174
Abbreviations: EP, error-prone; GS, gold standard.








0.00395{21.88586 3 0.693  (0.04564 þ 0.00268 3 0.693)/0.00174} ¼ 0.040.
b Assumed value for the association between C (receipt of a flu shot) and all-cause mortality from the literature
(hazard ratio ¼ 0.5). This value cannot be estimated from the data because C is unobserved in the main study and
Y is unobserved in the validation study.
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apply to settings in which X, C, and their combination are
multivariate-normal. Settings with nonnormal (e.g., binary)
confounders will be more complicated and possibly intrac-
table analytically. Nonetheless, experience in other problems
(e.g., effects of case-control matching (23), prediction for
multiple imputation (4)) suggests that normal cases can be
reasonable guides to scenarios involving categorical vari-
ables. Given the rough nature of external bias adjustments
and sensitivity analysis, we would expect similar practical
conclusions to hold for PSC. The major limitation of PSC
for sensitivity analysis, however, will be the lack of avail-
ability of cross-sectional validation studies that are repre-
sentative of the main study, and more specifically, possible
nontransportability of models.
The use of DAGs for propensity scores is nonstandard.
Furthermore, there may be different DAGs with which to
describe the PSC setting. The DAG we propose for PSC
allowed us to predict bias from PSC, however, and thus has
empirical validity, at least over the scenarios assessed in the
simulations. The primary drawback of path analysis in
this context is its assumption of linear associations among
all variables in the model. Furthermore, interactions be-
tween variables cannot be incorporated perfectly. The use
of linear regression for dichotomous exposures is also found
in instrumental-variable analysis (24).
Other criticisms of path analysis (25, 26) do not apply to
this context. We assume that we know the causal model apart
from the exposure effects; it is not deduced from the path
analysis. Path analysis using correlation coefficients depends
on the standard deviation of the variables concerned, but here
we are using regression coefficients, which are not affected
by the standard deviation (27, 28). Our primary assumption
then is that these effects are the same (i.e., the models are
transportable).
Conclusions from simulations are by definition restricted
to the scenarios assessed. Our previous simulations did not
consider scenarios with considerable asymmetry in strength
of confounding between observed and unobserved variables
which we have evaluated here.
We found that the magnitude and direction of bias en-
countered when applying PSC to control for a single con-
founder measured only in a cross-sectional validation study
may often be small and can be predicted on the basis of
a bias equation derived from DAGs and path analysis. To
do so, we need to assume a plausible value for the single
unobservable parameter, the relative risk associated with
the unobserved confounder. This is an important step towards
the understanding and implementation of PSC as a sensitivity
analysis. Its utility will depend on extension of the bias
formula to the multivariable setting.
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